Curaleaf has entered into a partnership with medicinal cannabis producer Australian Natural Therapeutics Group (ANTG).
Under this agreement, Curaleaf Laboratories will manufacture and distribute ANTG's range of products across the United Kingdom, significantly expanding access to medicinal cannabis for eligible patients and healthcare professionals.
© Curaleaf
Richard Hodgson, Managing Director, Curaleaf Laboratories, said: "This partnership marks a significant milestone for Curaleaf Laboratories as we continue to deliver on our commitment to support patient access to pharmaceutical-grade, evidence-based cannabis medicines. ANTG's reputation for excellence and scientific rigour aligns perfectly with our mission to set new standards in product quality and patient care."
Matt Cantelo, Founder and CEO, ANTG added: "Partnering with Curaleaf Laboratories brings together two organisations dedicated to quality and patient care. This collaboration represents an important step in our international growth strategy and our shared goal of improving patient outcomes through trusted, pharmaceutical-grade cannabis-based medicines."
For more information:
Curaleaf
[email protected]
curaleaf.com
